

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LERADO GROUP (HOLDING) COMPANY LIMITED**

(隆成集團(控股)有限公司)\*

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 1225)**

**BUSINESS UPDATE  
USE OF PROCEEDS**

Reference is made to the circular of the Company dated 28 August 2014 (the “**Circular**”) in relation to the Disposal. Unless otherwise defined, terms used in this announcement shall have same meanings as used in the Circular.

The Group originally intended to use the balance of the net proceeds from the Disposal, after declaration of special dividend, of approximately HK\$668.3 million for approximately HK\$480.0 million as expansion capital for the Medical Business and potential investment in connection with the Medical Business (the “**Proceeds for Medical Business**”); approximately HK\$120.0 million for investment opportunities in other business sectors that would benefit from the growing aging population and health consciousness in the PRC and approximately HK\$68.3 million as general working capital. In the past months, the Company has endeavored in exploring opportunities for potential investment and acquisition in connection with the Medical Business. However, no favorable opportunity was identified.

As disclosed in the annual results announcement of the Company dated 31 March 2015 in relation to the Company's prospect, given that the Directors with concrete financial knowledge and background and Company's strong cash position, the Directors are in the view that it is a suitable time for the Company to take an active approach in generating immediate revenue and diversifying the Company's business portfolio in other business sectors including securities trading, money lending business, other financial investment and property investment and development. After discussion among the Directors, in order to diversify the business opportunities, the Company would like to re-allocate approximately HK\$300.0 million for the proposed businesses apart from the Proceeds for Medical Business.

The Board is of the view that such re-allocation is fair and reasonable and in the interests of the Company and its shareholders as a whole.

**Shareholders and potential investors of the Shares should note that the above mentioned updates contain certain business development, plans and intents which may or may not materialize. Shareholders and potential investors of the Shares should exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Lerado Group (Holding) Company Limited**  
**HUANG Ying Yuan**  
*Chairman*

17 April 2015

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. HUANG Ying Yuan, Mr. HUANG Shen Kai, Mr. CHEN Chun Chieh and Mr. LAI Kin Chung, Kenneth as executive Directors, and Mr. MAK Kwong Yiu, Mr. YE Jianxin and Mr. CHERN Shyh Feng as independent non-executive Directors.*

*\* For identification purposes only*